Overview

Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

Status:
Not yet recruiting

Trial end date:
2026-11-01

Target enrollment:

Participant gender:

Summary

The study is investigating dysfunctions in neurocircuitry in regards to irritability with healthy controls (HC) and individuals with Major Depressive Disorder (MDD) by performing MRIs. The MDD group will also be randomized to receive ketamine or midazolam to investigate changes post-treatment in neurocircuitry with regards to irritability.

Phase:

Phase 2

Details

Lead Sponsor:

University of Texas Southwestern Medical Center

Treatments:

Ketamine
Midazolam